Karyopharm Therapeutics Inc. — 2016 Form 10-K Summary
Business context and reporting period
This annual report covers the fiscal year ended December 31, 2016. Karyopharm is a clinical-stage biotechnology company developing oral medicines targeting nuclear export, principally selinexor (KPT-330), an XPO1 inhibitor. The company had no drug-sales revenue and remained dependent on external financing. Its financial statements were audited by Ernst & Young LLP; the auditor did not provide an opinion on internal control over financial reporting.
Financial performance, liquidity and capital
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Contract and grant revenue | $0.154 million | $0.250 million |
| Research and development expense | $86.9 million | $97.7 million |
| General and administrative expense | $23.9 million | $21.6 million |
| Net loss | $109.6 million | $118.2 million |
| Net loss per share, diluted | $2.92 | $3.32 |
| Cash used in operating activities | $84.4 million | $94.0 million |
| Cash, cash equivalents and investments, including restricted cash | $175.5 million | $210.0 million |
| Working capital | $115.2 million | $162.5 million |
Operating loss was $110.7 million in 2016, compared with $119.1 million in 2015. Other income, primarily investment interest, was $1.3 million. Gross margin is not meaningful because the company had no product sales. The balance sheet showed $18.1 million in total liabilities, including $16.5 million of current liabilities; the filing reports no borrowings or material debt. Management expected existing cash and investments to fund its current operating plan and capital expenditures through the end of 2018, while also stating that substantial additional funding would be needed over time.
Fourth-quarter 2016 unaudited results: operating expenses were $27.2 million and net loss was $26.9 million, or $0.65 per share. The company raised $50.6 million net through its at-the-market share offering during 2016; shares outstanding rose to 41.9 million at year-end from 35.9 million a year earlier.
Material changes and developments
- Net loss narrowed by about 7% year over year and operating cash use fell by $9.6 million. R&D expense declined $10.8 million, mainly due to lower clinical-trial, preclinical and discovery spending; higher personnel and stock-based compensation partly offset the reductions.
- Selinexor development advanced in multiple myeloma, diffuse large B-cell lymphoma (DLBCL) and liposarcoma. Management planned to start the randomized Phase 3 BOSTON myeloma trial in early 2017; topline data were anticipated in 2019. STORM expansion data were expected in early 2018, and SEAL Phase 2 data in mid-2017.
- In March 2017, after an FDA inspection and Form 483 observations concerning procedures and documentation, the FDA placed selinexor trials under a partial clinical hold. New patients could not begin treatment, while certain responding patients could continue under updated consent. Karyopharm said it had submitted requested materials; lifting the hold was not assured.
- The Phase 2 SOPRA trial in older patients with relapsed or refractory AML was not expected to meet its primary endpoint of overall-survival superiority versus physician’s choice. Selinexor-arm complete responses were reported, but they did not translate into statistically superior overall survival.
Outlook, commentary and principal risks
Management expected operating expenses and losses to continue as trials progressed and the company prepared for potential commercialization. The central value driver was selinexor, but no candidate had marketing approval and the company had not demonstrated successful completion of a registration-stage trial. Accelerated approval in penta-refractory myeloma was an intention contingent on expanded STORM results and regulatory acceptance, not an assured outcome.
Key risks include the partial clinical hold and related safety-reporting requirements; clinical efficacy, safety and regulatory uncertainty; SOPRA’s failure to meet its primary endpoint; financing needs and potential dilution; dependence on third-party trial and manufacturing providers, with no long-term or redundant selinexor supply agreement; competition and reimbursement or pricing constraints; and reliance on patent protection. Management cited selinexor-related nausea, fatigue, anorexia, vomiting and thrombocytopenia, including severe thrombocytopenia in some patients. The filing also disclosed no material legal proceedings and no off-balance-sheet arrangements. Lease obligations totaled $8.1 million.
Important facts for investors to verify
- Whether and when the FDA lifted the selinexor partial clinical hold, and whether additional requirements affected trial enrollment or timing.
- Final, independently reviewed results from STORM and other selinexor studies, including safety, response durability and whether endpoints support any regulatory filing.
- How the SOPRA outcome affects the company’s AML development plans and resources.
- Actual cash burn, financing needs and runway relative to management’s end-of-2018 estimate; also assess dilution from future equity issuance.
- Clinical and commercial manufacturing capacity, supply continuity, and the status of any collaborations or commercialization preparations.